Last reviewed · How we verify
NCT03986775
Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
NA trial testing isomaltulose in Overweight and Obesity in 80 participants. Completed in 9 August 2017.
3 March 2017
Quick facts
| Lead sponsor | Beneo-Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 80 |
| Start date | 1 August 2016 |
| Primary completion | 3 March 2017 |
| Estimated completion | 9 August 2017 |
Drugs / interventions tested
- isomaltulose
- sucrose — full drug profile →
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
Sponsor
Beneo-Institute
Who can join
Adults 25 to 50, any sex, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of Isomaltulose Compared to Sucrose in Modulating Endothelial Function in Overweight Adults.
de Groot E, Schweitzer L, Theis S. · · 2020 · cited 4× · PMID 31947853 · DOI 10.3390/nu12010141
Verify or expand the search:
- PubMed search for NCT03986775
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of isomaltulose
Trials testing the same drug.
- NCT04596709 — Investigation of Blood Glucose and Insulin Response After Intake of Vitalose · NA · completed
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Beneo-Institute trials
Trials by the same sponsor.
- NCT05881018 — Investigating the Effects of Diet and Physical Activity on Esport Performance · NA · completed
- NCT05212545 — Effects of Prebiotics on Intestinal Colonization and Mood in a University Cohort · NA · completed
- NCT05581615 — Influence of Food Matrix on Prebiotic Efficacy in Inulin Type Fructans · NA · completed
- NCT04596709 — Investigation of Blood Glucose and Insulin Response After Intake of Vitalose · NA · completed
- NCT03457688 — Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03986775 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beneo-Institute
- Last refreshed: 17 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986775.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing